Back to Platforms

Platform 4: Advanced PK-PD AMR modelling

This platform in molecular pharmacology and pharmacokinetics-pharmacodynamics (PK-PD) led by the University of Liverpool provides new drug development models and approaches to help industry develop new agents to meet the challenge of antimicrobial resistance. It supports the discovery and development of novel therapeutics to tackle the world’s most critical, multi-drug-resistant infections.

The multi-drug-resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii are key threats to human health at a global scale. New drugs are urgently required, however robust tools to assess these compounds at the early therapeutic lead stage are poorly developed.

To support industrial innovation, we are extending a suite of model systems that enable new therapeutic solutions for Pseudomonas aeruginosa and Acinetobacter baumannii. These include new experimental model systems of hospital acquired pneumonia, which continues to be associated with unacceptably high mortality and developing engineered strains that display a variety of resistance mechanisms while remaining highly pathogenic.

For more information or to learn how your business can engage with this platform.

Email Dr Becky Jones-Phillips

Professor William Hope OBE (FRACP, FRCPA, PhD)

Platform Lead

Professor William Hope OBE (FRACP, FRCPA, PhD)

Dame Sally Davies Chair of AMR Research – Director, Centre of Excellence in Infectious Diseases Research – Co-Lead, NIHR Infectious Diseases National Specialty Group University of Liverpool.

Read more

Platform Lead

Dame Sally Davies Chair of AMR Research

Director, Centre of Excellence in Infectious Diseases Research

Co-Lead, NIHR Infectious Diseases National Specialty Group University of Liverpool.

Read more

Learn more about collaborating with iiCON

Discover more